We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

26 hedge funds and large institutions have $162M invested in GW Pharmaceuticals Plc American Depositary Shares in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

222% more capital invested

Capital invested by funds: $50.5M → $162M (+$112M)

100% more funds holding

Funds holding: 1326 (+13)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
26
Holders Change
+13
Holders Change %
+100%
% of All Funds
0.75%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
17
Increased
2
Reduced
2
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VM
1
VHCP Management
New York
$29.1M -$4.38M -138,424 -17%
PP
2
Prudential plc
United Kingdom
$25.5M
FCM
3
Farallon Capital Management
California
$24.3M
Fidelity Investments
4
Fidelity Investments
Massachusetts
$18.1M +$13.8M +435,227 New
RG
5
Redmile Group
California
$15M +$6.17M +194,957 +118%
O
6
OrbiMed
New York
$13.3M +$10.1M +320,200 New
Millennium Management
7
Millennium Management
New York
$6.27M +$2.69M +85,012 +129%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$6.03M
PC
9
Pier Capital
Connecticut
$4.94M +$3.77M +119,006 New
A
10
Abingworth
United Kingdom
$4.25M
BBA
11
Baker Bros. Advisors
New York
$3.91M +$2.98M +94,172 New
MHP
12
Manatuck Hill Partners
Connecticut
$3.03M +$2.31M +73,000 New
Morgan Stanley
13
Morgan Stanley
New York
$2.91M +$2.22M +70,030 New
VAM
14
Visium Asset Management
New York
$2.5M +$1.91M +60,291 New
Barclays
15
Barclays
United Kingdom
$1.19M +$914K +28,900 New
Neuberger Berman Group
16
Neuberger Berman Group
New York
$955K +$728K +23,000 New
Jane Street
17
Jane Street
New York
$511K +$409K +12,936 New
AIG
18
American International Group
New York
$275K -$93.6K -2,958 -31%
HAMF
19
Hatteras Alternative Mutual Funds
North Carolina
$249K +$190K +6,000 New
Renaissance Technologies
20
Renaissance Technologies
New York
$212K +$161K +5,100 New
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$14K +$10.8K +340 New
Wells Fargo
22
Wells Fargo
California
$12K +$9.49K +300 New
LFG
23
LifePlan Financial Group
Ohio
$8K +$5.76K +182 New
LTFS
24
Ladenburg Thalmann Financial Services
Florida
$8K +$6.33K +200 New
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$4K

GWPH Hedge Fund Activity: Q4 2013 in Review

26 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q4 2013, worth a combined $162M — up 222% from $50.5M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GWPH positions and 4 closed out — a net gain of 13 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $13.8M. The largest seller was Broadfin Capital, exiting entirely with an estimated $5.7M sold.

  • 26 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q4 2013, up from 13 in Q3 2013.
  • Funds reported $162M of GW Pharmaceuticals Plc American Depositary Shares stock for Q4 2013, up 222% quarter-over-quarter.
  • 17 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q4 2013 and 4 closed out, a net change of +13 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q4 2013 was Fidelity Investments, an estimated $13.8M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q4 2013 was Broadfin Capital, an estimated $5.7M sold.

Based on aggregated 13F filings for Q4 2013.